gp130/IL6ST 蛋白, Mouse (HEK293, His)

Glycoprotein 130 (gp130) is a trans-membrane protein, is the common signal-transducing receptor subunit of the interleukin-6 (IL-6) family^[1]. gp130 inhibits the cell growth and migration^[3], decreases the STAT3 phosphorylation induced by IL-6, and decreases IL-6-induced increase of Ki67. gp130 shows anti-tumor, anti-inflammation and anti-nociceptive activity^[4][5]. gp130/IL6ST Protein, Mouse (617a.a, HEK293, His) is a recombinant protein with a His label and is produced by HEK293 cells.

糖蛋白130 mRNA在人体内广泛表达，在隐静脉、心包、卵巢、网膜脂肪组织、腹膜、脾淋巴结和三叉神经节中表达水平最高。与胎儿器官相比，成人器官中gp130的表达显着增加。此外，与正常组织相比，gp130 在多种类型的癌症中高表达^[3]。
人 gp130 蛋白的氨基酸序列与小鼠和大鼠 gp130 蛋白的同源性较低。
当自分泌或旁分泌细胞因子诱导 gp130 和 α 受体亚基二聚化形成受体复合物时，gp130 信号传导启动，导致下游信号级联的激活，例如 JAK/STAT、PI3K/Akt、和 Ras/Raf/Mek/Erk1/2MAPK 通路。JAK/Stat3通路的激活诱导其靶基因表达，导致细胞生长、增殖（cyclin D、CDC25 A、c-Myc、survivin）、生存（survivin、Bcl-2、Bcl-X_L)、血管生成 (VEGF) 和细胞迁移（MMP-2、MMP-7 和 MMP-9）^[3]。
gp130 是一种 IL-6 拮抗剂，具有抗-肿瘤、抗炎和抗伤害活性^[4]。gp130 降低 IL-6 诱导的 STAT3 磷酸化，并降低 IL-6 诱导的 Ki67^[5] 增加。

1.Measured by its ability to inhibit the IL-6Rα enhancement of IL-6 activity on M1 mouse myeloid leukemia cells and the ED₅₀ is typically 0.6-3 μg/mL in the presence of 50 ng/mL human IL-6sR and 100 ng/mL human IL-6.
2.Measured by its ability to bind mouse IL-11Ra in a functional ELISA.
3.Immobilized Human gp130 at 5 μg/mL (100 μL/well) can bind Biotinylated Human IL-6 R alpha that produces 50% of the optimal binding response is found to be approximately ≤8 ng/mL.
4.Measured by its ability to inhibit IL-6-dependent proliferation of TF-1 cells. The ED₅₀ this effect is 0.1185 ng/mL in the presence of 4 μg/mL Recombinant Human IL-6 R alpha , corresponding to a specific activity is 8.44×10^6 units/mg.

• 
  Measured by its ability to inhibit IL-6-dependent proliferation of TF-1 cells. The ED₅₀ this effect is 0.1185 ng/mL in the presence of 4 μg/mL Recombinant Human IL-6 R alpha, corresponding to a specific activity is 8.44×10⁶ units/mg.

Mouse

HEK293

C-His

Q00560/NP_034690 (Q23-E617)

16195  [NCBI]

QLLEPCGYIYPEFPVVQRGSNFTAICVLKEACLQHYYVNASYIVWKTNHAAVPREQVTVINRTTSSVTFTDVVLPSVQLTCNILSFGQIEQNVYGVTMLSGFPPDKPTNLTCIVNEGKNMLCQWDPGRETYLETNYTLKSEWATEKFPDCQSKHGTSCMVSYMPTYYVNIEVWVEAENALGKVSSESINFDPVDKVKPTPPYNLSVTNSEELSSILKLSWVSSGLGGLLDLKSDIQYRTKDASTWIQVPLEDTMSPRTSFTVQDLKPFTEYVFRIRSIKDSGKGYWSDWSEEASGTTYEDRPSRPPSFWYKTNPSHGQEYRSVRLIWKALPLSEANGKILDYEVILTQSKSVSQTYTVTGTELTVNLTNDRYVASLAARNKVGKSAAAVLTIPSPHVTAAYSVVNLKAFPKDNLLWVEWTPPPKPVSKYILEWCVLSENAPCVEDWQQEDATVNRTHLRGRLLESKCYQITVTPVFATGPGGSESLKAYLKQAAPARGPTVRTKKVGKNEAVLAWDQIPVDDQNGFIRNYSISYRTSVGKEMVVHVDSSHTEYTLSSLSSDTLYMVRMAAYTDEGGKDGPEFTFTTPKFAQGEIE

80-90 kDa.

• 
  Greater than 95% as determined by reducing SDS-PAGE.

无菌粉末

Lyophilized from a 0.2 μm filtered solution of PBS or 20 mM PB, 150 mM NaCl, pH 7.4.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.

• [1]. Cao Y, et al. Glycoprotein 130 is associated with adverse postoperative clinical outcomes of patients with late-stage non-metastatic gastric cancer. Sci Rep. 2016 Dec 5;6:38364.  [Content Brief]

  [2]. Nogueira-Silva C, et al. The role of glycoprotein 130 family of cytokines in fetal rat lung development. PLoS One. 2013 Jun 24;8(6):e67607.  [Content Brief]

  [3]. Xu S, et al. gp130: a promising drug target for cancer therapy. Expert Opin Ther Targets. 2013 Nov;17(11):1303-28.  [Content Brief]

  [4]. Boettger MK, et al. Differential effects of locally and systemically administered soluble glycoprotein 130 on pain and inflammation in experimental arthritis. Arthritis Res Ther. 2010;12(4):R140.  [Content Brief]

  [5]. Hong J, et al. Recombinant soluble gp130 protein reduces DEN-induced primary hepatocellular carcinoma in mice. Sci Rep. 2016 Apr 15;6:24397.  [Content Brief]